These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7762010)

  • 21. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
    Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
    Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
    Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
    Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
    Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
    Moon YS; Chung KC; Gill MA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide.
    Hoban DJ; Jones RN; Yamane N; Frei R; Trilla A; Pignatari AC
    Diagn Microbiol Infect Dis; 1993; 17(4):299-305. PubMed ID: 8112045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-activity relationships of carbapenem and penem compounds for the convulsive property.
    Sunagawa M; Matsumura H; Fukasawa M
    J Antibiot (Tokyo); 1992 Dec; 45(12):1983-5. PubMed ID: 1490893
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
    Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
    J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.
    Yang Y; Bhachech N; Bush K
    J Antimicrob Chemother; 1995 Jan; 35(1):75-84. PubMed ID: 7768785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tolerance and safety of carbapenems: the use of meropenem].
    Lizasoaín M; Noriega AR
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():73-7. PubMed ID: 9410074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY; Livermore DM
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem.
    Schliamser SE; Broholm KA; Liljedahl AL; Norrby SR
    J Antimicrob Chemother; 1988 Nov; 22(5):687-95. PubMed ID: 3209527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
    Kim J; Ha JR; Oh SW; Kim HG; Lee JM; Lee DG; Lee SH; Kim JG
    Biol Pharm Bull; 2007 Mar; 30(3):575-9. PubMed ID: 17329859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.